About this research
This policy briefing summarises findings from an ongoing PhD project focused on the ethical implementation of collective nanosystems in cancer clinical trials. It seeks to identify regulatory gaps and support ethics committees, regulators, and policymakers in adapting and evolving their ethical frameworks for collective nanosystems in future cancer clinical trials. The PhD used participatory approaches, including interviews, focus groups, and public engagement activities. This involved regulators, policymakers, nanomedicine researchers, healthcare professionals, cancer patients, carers, private and third sector organisations, and interested members of the public. Participatory approaches highlighted the importance of consultation and co-design for the acceptance of future collective nanosystems in cancer trials.